Company Summary

Company Overviews

海思科医药集团成立于2000年,是一家以新药研发为核心,销售能力特别突出的医药类集团化上市公司。集团是肠外营养行业领导者,在肝病领域细分市场占据重要地位,是全国排名前列的肝病用药生产销售基地,现有员工超过1900名。
公司自2012年1月17日在深圳证券交易所A股上市以来,在资本市场有着良好的表现,目前股票市值约270亿人民币,A股排名前380、中小板排名前59、全国医药上市公司中长期排名25、化学药子行业上市公司排名第7 位、上市公司市值管理绩效百佳榜第9位、中国上市公司市值管理绩效百佳、中国医药行业最具影响力榜单成长50强企业、2014福布斯中国上市潜力企业100强位列第三位、医药类企业第一位、2015福布斯中国潜力企业。
公司坚持以新产品研发作为企业发展的核心驱动力,经过多年积累与实践,公司已建立450人的研发团队,其中包括50余名博士、近百名硕士,95%以上成员具有药学或相关专业本科以上学历,公司研发团队技术水平、团队人数在国内医药企业处于领先水平,公司首仿成功率行业第一,近五年新药批件取得数量全国第三。
公司于2015年正式进军高端医疗器械市场。

Rating Reviews

Rating is calculated based on 1 review and is evolving.

Featured Reviews

Project Manager
3.7
28 August 2026
Solid Pharma Role with Room for Leadership Improvement
Pros: Working at Huisun Pharmaceutical Group has been a valuable experience in the healthcare sector. The emphasis on teamwork and the supportive atmosphere among colleagues make daily operations smooth. There are genuine opportunities for professional development and skill enhancement. I've appreciated the stability and the chance to contribute to meaningful projects within a well-established pharmaceutical company.
Cons: While leadership is generally competent, there's a noticeable gap in transparent communication regarding long-term strategic decisions and changes. This can sometimes lead to confusion or misaligned efforts across different departments. Clearer articulation of vision and direction would help everyone feel more connected to the company's overarching goals.
Advice to Management: Invest more in transparent, two-way communication channels from senior leadership to all levels. Regular town halls or Q&A sessions addressing strategic direction and potential challenges would foster greater trust and alignment across the organization, particularly in navigating the fast-paced pharmaceutical market.
Show more
See all reviews >

Common Questions About 海思科医药集团股份有限公司

What is the typical salary range for a pharmaceutical sales representative at Hisun Pharmaceutical Group in China?
See all questions >

See More Companies